老年冠心病病人血脂达标率及其影响因素的研究

doi:10.3969/j.issn.1003-9198.2021.05.012

摘要/Abstract

摘要： 目的了解规律行二级预防的老年CHD病人血脂达标率情况,并进一步探讨与其相关的影响因素。方法纳入 2017 年1月至 2018 年 1月期间我院收治入院的,均已确诊CHD 1年以上且规范行二级预防的老年病人 450 例。收集病人的临床资料,包括性别、年龄、CHD病程、既往病史、实验室检查结果、LVEF等并进行整理分析。依据指南将病人分别按照LDL-C＜1.8 mmol/L 和非HDL-C＜2.6 mmol/L为达标分组, 对可能影响达标率的因素进行单因素和多因素分析。结果本研究中有 192例(42.67%) 病人 LDL-C 水平达标;有 274 (60.89%)例非HDL-C 水平达标。在单因素分析过程中,影响 LDL-C 达标率和非HDL-C 达标率的因素均为性别、DM、DM病程、血糖控制不住,及TC、TG、血糖水平(P＜0.05)。性别、DM和血糖控制不佳在多因素回归分析中仍是影响 LDL-C 达标的因素;影响非HDL-C 达标的多因素回归分析结果为性别和血糖控制不佳。结论已行二级预防的老年CHD病人的血脂达标率较高,性别和血糖控制不住是影响老年CHD病人血脂达标率的主要因素。

关键词: 老年人, 冠心病, 血脂达标率, 影响因素

Abstract: Objective To understand the success rate of blood lipid among the elderly patients with coronary heart disease(CHD) undergoing secondary prevention regularly and to explore the risk factors. Methods This study enrolled 450 elderly patients who were diagnosed with CHD for more than one years during January 2017 to January 2018, and regularly received the secondary prevention of CHD. The patients’ characteristics, including gender, age, course of CHD, medical history (hypertension, diabetes), laboratory results such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (N-HDL-C), fasting plasma glucose (FPG), creatinine, glycosylated hemoglobin, examination results (coronary angiography, cardiac ultrasound, carotid ultrasound) were collected and analyzed. The patients were divided into eligible group and ineligible group according to the guidelines, whether LDL-C was <1.8 mmol /L or N-HDL-C was <2.6 mmol /L.The risk factors of the success rate of blood lipid were analyzed by univariate analysis and multivariate analysis. Results Among the 450 elderly patients with CHD, 192(42.6%) patients achieved the target level of LDL-C,while 274(60.89%) patients achieved the target level of N-HDL-C. The univariate analysis showed that the influencing factors of the LDL-C and N-HDL-C success rate were gender, diabetes, serum glucose level and poor glucose control (P ＜ 0.05). In multivariate regression analysis, gender, diabetes and poor glucose control were independent factors that influenced LDL-C success rate, and gender and poor glucose control were influencing factors of N-HDL-C success rate. Conclusions The elderly patients with CHD undergoing second prevention have higher success rate of serum lipid. Gender and diabetes are the main factors affecting the serum lipid success rate in the elderly patients with CHD.

Key words: aged, coronary heart disease, success rate of blood lipid, influencing factors

中图分类号:

R 543.3

张金莲, 刘焕兵, 胡美迪, 江长文. 老年冠心病病人血脂达标率及其影响因素的研究[J]. 实用老年医学, 2021, 35(5): 479-482.

ZHANG Jin-lian, LIU Huan-bing, HU Mei-di, JIANG Chang-wen. Study on success rate of blood lipid and its influencing factors in elderly patients with coronary heart disease[J]. Practical Geriatrics, 2021, 35(5): 479-482.

参考文献

[1] 陈伟伟, 高润霖, 刘力生, 等. 《中国心血管病报告 2017》概要[J]. 中国循环杂志, 2018, 33(1):1-8.
[2] LIU X, YU S, MAO Z, et al. Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study[J]. Lipids Health Dis, 2018, 17(1):119.
[3] GUPTA A, MACKAY J, WHITEHOUSE A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial[J]. Lancet, 2018, 392(10153):1127-1137.
[4] 唐田, 祁丹妮, 高铭鑫, 等. 弥漫性冠状动脉病变患者血脂异常的临床观察与探讨[J]. 中国医药, 2019(1):22-25.
[5] NATARAJAN P, YOUNG R, STITZIEL N O, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting[J]. Circulation, 2017, 135(22):2091-2101.
[6] 于淼欣, 张润华, 田蕊, 等. 北京市石景山区血脂异常知晓率及治疗率和控制率的流行病学研究[J]. 中国临床保健杂志, 2019, 22(3):298-303.
[7] GUPTA A, THOMPSON D, WHITEHOUSE A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase[J]. Lancet, 2017, 389(10088):2473-2481.
[8] 《中国成人血脂异常防治指南(2016年修订版)》补充说明[J]. 中国循环杂志, 2017, 32(1):53.
[9] CHENG A Y, LEITER L A. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. Curr Opin Cardiol, 2006, 21(4):400-404.
[10]RIDKER P M, MORA S, ROSE L. Percent reduction in LDL-C cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents[J]. Eur Heart J, 2016, 37(17):1373-1379.
[11]WADHERA R K, STEEN D L, KHAN I, et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality[J]. J Clin Lipidol, 2016, 10(3):472-489.
[12]LI Y H, UENG K C, JENG J S, et al. 2017 Taiwan lipid guidelines for high risk patients[J]. J Formos Med Assoc, 2017, 116(4):217-248.
[13]AN T, SONG Y, YANG Y, et al. Non-HDL-C-cholesterol to HDL-C-cholesterol ratio is an independent risk factor for liver function tests abnormalities in geriatric population[J]. Lipids Health Dis, 2018, 17(1):296.
[14]JACOBSON T A, ITO M K, MAKI K C, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report[J]. J Clin Lipidol, 2015, 9(2):129-169.
[15]仁晖, 陈红, 宋俊贤, 等. 65岁以上老年患者血脂水平及达标率随年龄变化的趋势[J]. 中华老年心脑血管病杂志, 2015, 17(7):693-696.